Impact of regulatory events on JAK inhibitor prescribing in rheumatoid arthritis: Insights from the French MAJIK Registry

Marie-Elise Truchetet; Clément Prati; Pascale Thevenot; Christophe Bologna; Guillermo Carvajal Alegria; Claire Immediato Daien; Divi Cornec; Emmanuelle Dernis; Bruno Fautrel; Antoine Pariente; Christian Roux; Jean-Hugues Salmon; Jérémie Sellam; Emilie Hucteau; Julien Bezin; Jérôme Avouac

doi:10.1016/j.jbspin.2025.106021

Impact of regulatory events on JAK inhibitor prescribing in rheumatoid arthritis: Insights from the French MAJIK Registry

Joint Bone Spine. 2026 Mar;93(2):106021. doi: 10.1016/j.jbspin.2025.106021. Epub 2025 Dec 22.

Authors

Marie-Elise Truchetet¹, Clément Prati², Pascale Thevenot³, Christophe Bologna⁴, Guillermo Carvajal Alegria⁵, Claire Immediato Daien⁶, Divi Cornec⁷, Emmanuelle Dernis⁸, Bruno Fautrel⁹, Antoine Pariente¹⁰, Christian Roux¹¹, Jean-Hugues Salmon¹², Jérémie Sellam¹³, Emilie Hucteau¹⁴, Julien Bezin¹⁰, Jérôme Avouac¹⁵

Affiliations

¹ University Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, 33000 Bordeaux, France; CHU de Bordeaux, FHU ACRONIM, Centre national de référence des maladies auto-immunes et systémiques rares Est/Sud-Ouest (RESO), 33000 Bordeaux, France. Electronic address: marie-elise.truchetet@chu-bordeaux.fr.
² Université Marie et Louis Pasteur, UFR Santé, UMR1098, EFS, INSERM, Besançon, France; Department of rheumatology, University Hospital Besançon, 25000 Besançon, France.
³ French Society of Rheumatology, Paris, France.
⁴ Centre de rhumatologie de Bayonne, Bayonne, France.
⁵ Unité Propre de Recherche, Centre National de la Recherche Scientifique, 4301 Centre de Biophysique Moléculaire, Département NanoMédicaments et NanoSondes, 31, avenue Monge, 37200 Tours, France; Université de Tours, Unité de Formation et de Recherche de Médecine, 10, boulevard Tonnellé, BP3223, 37032 Tours Cedex 1, France; Centre Hospitalier Universitaire de Tours, Service de rhumatologie, 37044 Tours Cedex 9, France.
⁶ Montpellier University, CHU de Montpellier, Inserm U1046, CNRS UMR 9214, Montpellier, France.
⁷ LBAI, UMR 1227, Univ Brest, Inserm, CHU Brest, Brest, France.
⁸ Sorbonne University, Assistance Publique Hôpitaux de Paris, GH Pitié Salpêtrière, Dept of Rheumatology, INSERM UMRS 1136, CRI-IMIDIATE Clinical Research Network, 75013 Paris, France.
⁹ Service de rhumatologie, hôpital Pitié-Salpétrière, 75013 Paris, France.
¹⁰ University Bordeaux, INSERM, BPH, team AHeaD, U1219, 33000 Bordeaux, France; CHU de Bordeaux, Pharmacoepidemiology and Medicines Use, INSERM, U1219, 33000 Bordeaux, France.
¹¹ University Cote d'Azur, Rheumatology department, CHU de Nice, Nice, France.
¹² Department of Rheumatology, University of Reims Champagne-Ardenne (URCA), Reims University Hospital, 51100 Reims, France.
¹³ Rheumatology Department, Sorbonne University-AP-HP, CRSA INSERM 938, Saint-Antoine Hospital, Paris, France.
¹⁴ University Bordeaux, INSERM, BPH, team AHeaD, U1219, 33000 Bordeaux, France.
¹⁵ Rheumatology Department, Cochin Hospital, Assistance publique-Hôpitaux de Paris (AP-HP). Centre - Université Paris Cité, 75014 Paris, France.

PMID: 41443533
DOI: 10.1016/j.jbspin.2025.106021

No abstract available

Keywords: JAK inhibitors; Pharmacovigilance Risk Assessment Committee (PRAC); Registry; Rheumatoid arthritis.

Publication types

Letter